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Abstract:  An important host factor for hepatitis C virus (HCV) is microRNA-122  
(miR-122). miR-122 is a liver-specific member of a family of small, non-coding RNA 
molecules known as microRNAs that play major roles in the regulation of gene expression 
by direct interaction with RNA  targets. miR-122 binds directly to two sites in the   
5′ untranslated region (UTR) of HCV RNA and positively regulates the viral life cycle. 
The mechanism by which this regulation occurs is still not fully understood. There has 
been a great deal of interest in potential therapeutics based on small RNAs, and targeting 
miR-122 to combat HCV is one of the furthest advanced. Chemical inhibitors of miR-122 
can be introduced into mammals intravenously and result in potent and specific 
knockdown of the microRNA, with no detectable adverse effects on liver physiology. This 
strategy was recently applied to chimpanzees chronically infected with HCV and resulted 
in a sustained reduction in viral load in the animals. Inhibition of miR-122 therefore 
presents a very attractive novel approach to treating HCV, a virus for which improved 
therapeutics are urgently needed. 
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1. microRNAs: versatile regulators of gene expression 
In the last 10 years there have been enormous advances in our understanding of the role of small 
non-coding RNA molecules in the regulation of eukaryotic gene expression. microRNAs (miRNAs) 
are a particularly important class of small RNA. They have been implicated in various human diseases, 
including a number of viral infections, suggesting that future therapeutics may be able to exploit 
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aspects of this biology. This review concerns the role for a specific miRNA, miR-122, in the HCV life 
cycle, and its potential as an anti-HCV target. 
miRNAs are 21-23 nucleotide (nt) non-coding RNA molecules that are expressed by a broad range 
of eukaryotic species [1]. They are encoded in the genome and transcribed, usually by RNA 
polymerase II, as part of long primary miRNAs (pri-miRNAs). These may be unique transcripts, 
introns of coding mRNAs, or polycistronic transcripts containing a cluster of miRNAs [2].  
Pri-miRNAs undergo nuclear processing by the Microprocessor complex to generate a precursor 
miRNA (pre-miRNA). Pre-miRNAs are subject to nuclear export, and cytoplasmic processing by the 
enzyme Dicer, to yield the mature, single-stranded miRNA [2]. In the most recent release of miRBase 
(version 15), 940 different miRNAs have been identified in humans [3]. In higher organisms, miRNA 
expression is specialized according to both tissue type and developmental stage [4], and de-regulation 
of expression of certain miRNAs is associated with cancer [5]. 
There is considerable overlap between the miRNA pathway and the process of RNA interference 
(RNAi). RNAi is induced by long, double-stranded RNA, which is processed by Dicer to produce  
21-23 nt RNA duplexes known as short interfering RNAs (siRNAs) [6]. Both miRNAs and siRNAs 
associate with a complex of proteins that is necessary for their function. This is known as the   
RNAi-induced silencing complex (RISC), and the siRNA and miRNA-directed complexes are 
designated siRISC and miRISC, respectively. miRNAs that encounter exactly complementary targets 
act similarly to siRNAs and cleave the target RNA. This is the major mechanism of miRNA activity in 
plants, but very unusual in animals; however, this interchangeability of function indicates that the 
miRISC and siRISC are likely to share many common features [6]. The exact identity of the two 
RISCs is not certain, and it is possible that specialized versions may exist. A member of the argonaute 
protein family is an essential component; there are four such proteins in mammals (Ago1-4), of which 
only Ago2 can mediate RNA cleavage. Any of the four Ago proteins appear to be able to mediate 
miRNA activity in mammals, which also requires one of the three GW182 proteins (TNRC6A-C) [1]. 
Most animal miRNAs act by binding to imperfectly complementary target sites. Several algorithms 
have been used to predict miRNA target sites with varying degrees of success. Analysis of target sites 
has revealed some indicators of functional sites, most notably direct complementarity to the miRNA 
‘seed’, comprising nt 2-7 or 2-8 from the 5′ end [7]. Animal miRNAs usually bind to sites in the 3′ 
untranslated region (UTR) of mRNAs, resulting in reduced production of the corresponding protein 
[7]. There is still considerable debate about the underlying mechanism. Different groups have observed 
translation repression either at initiation or post-initiation, and RNA degradation is also apparent [1]. 
Current evidence would suggest that the translation block occurs at the level of initiation and that RNA 
degradation occurs as a consequence of this [8], but it is possible that different miRNA-target pairs or 
cellular conditions may result in different consequences. 
There are many examples of interaction between the miRNA pathway and viral infection. A number 
of DNA viruses, in particular the herpesviruses, encode their own miRNAs [9]. These viral miRNAs 
repress viral or cellular targets and may be important in establishing patterns of latent or lytic infection. 
Viral infection can also regulate the expression of cellular miRNAs [10]. There is evidence that 
cellular miRNAs can bind to target sites in certain viruses, notably human immunodeficiency virus-1 
(HIV-1), and repress production of the virus, but it is not certain whether this is really a 
physiologically relevant antiviral mechanism [9]. There is currently only one known example of a Viruses 2010, 2                               
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cellular miRNA that has a direct, positive effect on a viral life cycle; this is the interaction between 
miR-122 and HCV. 
2. miR-122 and HCV 
miR-122 is conserved, both in sequence and in its liver-specific expression pattern, from humans to 
zebrafish [4,11]. It accounts for around 70% of the total miRNA content of liver [4]. HCV is a positive 
sense RNA virus that infects the liver, frequently establishing persistent infections that can eventually 
result in liver cirrhosis and carcinoma [12]. The HCV RNA genome is 9.6 kilobases (kb) in length and 
consists of a single coding region flanked by structured 5′  and 3′  UTRs that are important for 
replication [13]. Translation of the viral polyprotein is driven by an internal ribosome entry site (IRES) 
in the 5′ UTR of the viral RNA. This IRES is unusual in its ability to recruit the 40S ribosomal subunit 
directly and initiate protein synthesis using a minimal subset of eukaryotic translation initiation factors 
[14]. The polyprotein is cleaved by viral and cellular proteases to produce mature structural and 
nonstructural proteins. Replication of the viral RNA then proceeds via a negative strand intermediate 
in membrane-bound replication complexes [13]. 
The role for miR-122 in HCV infection was first demonstrated by sequestration of endogenous 
miR-122, which led to a substantial reduction in HCV RNA in human liver cells that contain HCV 
replicons [15]. This is due to a direct interaction between miR-122 and two adjacent binding sites, 
which both have seed match complementarity to the miRNA [16]. Interestingly, these binding sites are 
in the 5′ UTR of the viral RNA (Figure 1). They are located in a single-stranded region of RNA 
immediately upstream of the HCV IRES, and are conserved across HCV genotypes. Mutagenesis of 
the miR-122 binding sites indicates that both sites are necessary for HCV replication to occur 
efficiently [16]. In an infectious HCV system, site 1 is absolutely required for infection, whereas the 
requirement for site 2 can be overcome by overexpression of miR-122 [17].  
It is not yet clear how miR-122 regulates HCV, although a positive role for RISC components in an 
infectious virus cell culture system suggests that this is a RISC-dependent process [18]. There has been 
some debate about whether or not viral translation is activated by the miRNA [15,19]. A recent study 
by Jangra et al. demonstrated that miR-122 does mediate a positive effect on HCV translation, but that 
this is not sufficient to explain its effects on replication of the virus [17]. This implies that a second 
mechanism of regulation is in play. The identity of this mechanism remains elusive, as miR-122 had 
little effect on new HCV RNA synthesis when this was measured directly by thiouridine labeling [20]. 
It is possible that an effect on viral RNA turnover may be involved, or that a role for miR-122 at a 
specific stage of the viral life cycle has been missed by previous experiments. A better understanding 
of the mechanistic details of the interaction between miR-122 and HCV will be important when 
considering miR-122 as a target for HCV therapy.  
HCV infection is currently treated with a combination of pegylated interferon-α and ribavirin. This 
is poorly tolerated and ineffective in a high proportion of patients, and novel therapies are urgently 
needed [12]. The role for miR-122 as an important, possibly essential, host factor for HCV makes it an 
attractive target for antiviral therapy. The rapid evolution of RNA viruses means that the development 
of resistance is frequently associated with the direct targeting of viruses. Using a host factor as a target 
has the potential to avoid this problem. The recent development of effective miRNA inhibitors that can Viruses 2010, 2                               
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be administered in vivo suggested that direct inhibition of miR-122 would be a good strategy for a new 
HCV therapy.  
Figure 1. A schematic of the HCV RNA genome is shown, with the miR-122 binding 
region expanded. miR-122, in collaboration with the RISC, binds directly to two adjacent 
seed matches (highlighted in blue) in the HCV 5′ UTR. This results in activation of both 
HCV translation and a further, unidentified stage of the replication cycle. Inhibitors can be 
directed against miR-122 to block binding to its target sites and reduce HCV replication.  
 
 
3. miRNA inhibition as a therapeutic tool 
The study of miRNAs has been greatly facilitated by the use of antisense oligonucleotides as 
inhibitors. The first application of this approach used an RNA oligomer complementary to the miRNA 
let-7, with 2′-O-methyl (2′-OMe) modifications at each position [21]. 2′-OMe RNA was chosen Viruses 2010, 2                               
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because it is resistant to cellular ribonucleases, and because it is bound by the complementary miRNA 
in association with the RISC. This is a crucial feature for the use of such molecules as inhibitors; it 
provides much greater efficacy than would be possible with simple hybridization to a complementary 
target, it allows the use of low (nanomolar) quantities of the inhibitor, greatly reducing the possibility 
of off-target effects, and the sequestration of the miRNA in its functional complex prevents its 
interaction with target RNA in a stable fashion. This oligomer effectively prevented let-7 action in 
vitro, in cultured HeLa cells following transfection using a liposomal reagent, and in C. elegans after 
injection. The molecule was non-toxic in C. elegans [21].  
The characteristics of these 2′-OMe inhibitors  –  notably tight binding at low concentration, 
specificity of action, and lack of associated toxicity – suggest that inhibition of miRNAs by similar 
methods might be a promising avenue for drug development. The success of this method in C. elegans 
is also important as it suggests that inhibition is possible in whole animals. This strategy, therefore, has 
much potential for therapeutics, as the expression of specific miRNAs is intimately connected with 
development and cell physiology, and therefore with disease. The greatest advances in this area have 
been directed at reducing HCV viral load by targeting miR-122, the focus of this review. However, 
miRNA-based medicines have much broader potential, particularly in cancer treatment, as there is a 
strong association between expression of certain miRNAs and development of certain tumors [5]. 
Since the initial studies with 2′-OMe oligomers, different chemistries have been tested to try to 
optimize binding affinity, stability and uptake of similar miRNA inhibitors. Several different 2′ sugar 
modifications that should increase binding affinity were tested in an assay for miR-21 inhibition. 
Locked nucleic acid (LNA), 2′-O-methoxyethyl (2′-MOE), or 2’-fluoro (2′-F) modifications to the 
sugar all improved the inhibition properties of the oligomer when compared to a 2′-OMe modification 
[22]. The effect on the miRNA varies according to the inhibitor used. LNA-modified oligomers form 
stable complexes with the target miRNA, whereas some other modifications result in degradation of 
the target, and some do not [23]. Functional readouts are therefore necessary to establish the efficiency 
of inhibition. Different sugar modifications have been combined to create inhibitors with improved 
properties. A 2′-F/MOE-modified oligomer was the most effective of several molecules tested for 
inhibition of miR-122 in cell culture [23]. LNA modification imparts increased binding affinity and 
specificity when incorporated at some positions in a DNA oligonucleotide. 16 nt oligomers with a 
mixture of DNA and LNA bases have been successfully used to target miR-122 in vivo [24-26]. 
Delivery of miRNA inhibitors to tissues presents technical challenges. Carriers such as liposomes 
are widely used in cell culture to protect the oligonucleotide from degradation and allow delivery 
across the hydrophobic cell membrane [27]. Similar delivery methods could be used in vivo, but 
successful delivery to the liver has been possible without packaging. A cholesterol-conjugated 
antisense oligonucleotide, known as an ‘antagomir’, directed against miR-122 was administered by 
intravenous injection and was  delivered to the liver [28]. Peptide nucleic acid (PNA) oligomers 
coupled to a cell-penetrating peptide or four lysine residues could enter cells without transfection 
reagent and inhibit miR-122 in cell culture [29]. A PNA-based, lysine-conjugated oligomer was also 
used to inhibit the oncogenic miR-155 in B cells in vivo [30].  
Successful systemic delivery of antisense oligonucleotides has also been  accomplished without 
conjugation by incorporating a phosphorothioate backbone. Phosphorothioate modification improves 
the stability of the oligomer, delays plasma clearance, and allows entry into tissues [31]. miR-122 has Viruses 2010, 2                               
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been targeted by this method using a 2′-MOE inhibitor administered by intraperitoneal injection. A 
phosphorothioate backbone was also used in the LNA-based miR-122 inhibitors, and allowed very 
effective miR-122 inhibition following intravenous injection [24-26].  
Systemic delivery by intravenous injection is desirable, and the success with these miR-122 
inhibitors indicates that it is possible to target liver miRNAs by this method. The liver specificity of 
miR-122 expression means that side effects of drug delivery to other tissues are not likely to be a 
problem, unless the drug has non-specific toxic effects. Different miRNAs in other tissues are likely to 
prove more difficult to target and may require localized delivery mechanisms, or different strategies 
[27]. One possibility is to use miRNA ‘sponges’, DNA plasmids encoding an RNA that contains 
multiple copies of a target for a particular miRNA. These RNAs bind the endogenous miRNA and 
reduce its availability for endogenous targets [32]. As sponges are DNA-based, they have the potential 
for introduction into cells by viral delivery, which could be very useful when targeting certain tissues. 
However, this method is not as effective or simple as direct inhibition of the miRNA. 
4. Successful inhibition of miR-122 in animals 
The sequence of miR-122 is completely conserved in mammals, which has allowed optimization of 
targeting strategies in animal models. Inhibition of miR-122 in mice was first accomplished using an 
‘antagomir’  [28]  and a 2′-MOE-modified oligomer with a phosphorothioate backbone [33]. Both 
studies yielded similar results. 
An obvious concern when targeting a miRNA is that this will result in changes in expression of its 
endogenous targets, with potentially damaging consequences. Encouragingly, the animals in these 
studies did not show any evidence of liver toxicity, but did experience a substantial reduction in 
plasma cholesterol [28]. Microarray analysis was used to identify mRNAs that change in expression 
when miR-122 is inhibited. A high proportion of mRNAs that increased on miR-122 inhibition have 
seed matches for miR-122 in the 3′ UTR, and are therefore likely to be direct endogenous targets for 
the miRNA. Several mRNAs encoding proteins that are involved in cholesterol synthesis were 
downregulated on miR-122 inhibition, suggesting that this pathway is regulated indirectly. miR-122 
inhibitors therefore have potential therapeutic value in both HCV and cholesterol disorders. 
miR-122 inhibition in mice was also achieved using an  inhibitor containing an optimized 
combination of DNA and LNA-modified bases complementary to nt  1-16 of miR-122, with a 
phosphorothioate backbone [24]. The LNA inhibitor was delivered to murine liver following 
intravenous injection, and effective sequestration of miR-122 was observed by formation of a 
heteroduplex with the inhibitor, increases in the mRNA level of endogenous miR-122 targets, and a 
reduction in plasma cholesterol. The doses required were much lower than in the antagomir 
experiments, so an LNA-based strategy seems the most promising approach to take for future 
therapeutics. 
LNA-based oligomers were then tested in a non-human primate, the African green monkey. The 
results obtained were very similar to those in mice, with formation of miR-122-inhibitor complexes, 
increases in the level of endogenous targets, a reduction in plasma cholesterol, and no detectable liver 
toxicity [25]. The animals were treated with three intravenous injections and observed over the course 
of several weeks. Plasma cholesterol reduction was sustained for five to seven  weeks,  and  then Viruses 2010, 2                               
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returned to pre-treatment levels as LNA-antimiR-122 was cleared from the liver. The results of this 
study were encouraging for therapeutic development, firstly because the inhibitor shows similar effects 
and similar lack of toxicity in primates as in mice, implying that it could also be effective in humans, 
and secondly because the effects of the inhibitor are sustained and reversible, which are desirable 
properties for a drug. 
5. miR-122 inhibition reduces HCV viral load in chimpanzees 
LNA-antimiR-122, now known as SPC3649, has recently been used to inhibit miR-122 in 
chimpanzees chronically infected with HCV [26]. The animals were treated at weekly intervals over a 
12-week period. Excitingly, three out of the four animals treated showed a sustained reduction in viral 
load. The fourth animal had fluctuations in viral load throughout the study, making it difficult to 
assess. This was one of two animals that received a low dose (1 mg/kg). This was considerably less 
effective than the high dose (5 mg/kg); even the animal that responded to the low dose only had a 
reduction in liver HCV RNA of 1.3 orders of magnitude, compared to 2.3 orders of magnitude in HCV 
RNA in the liver, and 2.6 in the serum, of the high dose animals [26]. The reasons for this are not 
clear, as both dosing regimes resulted in sequestration of all detectable miR-122 into a heteroduplex 
with the inhibitor. It is possible that undetectable levels of miR-122 remaining after the low dose 
therapy were sufficient to support HCV replication; we know little about the stoichiometry of the  
miR-122-HCV interaction in infected liver. There was no significant change in expression of 
endogenous miR-122 target genes in the non-responder, supporting the theory that miR-122 was not 
effectively targeted in this animal [26]. Heteroduplex formation between miR-122 and the inhibitor is 
therefore not a very reliable method of assessing the efficiency of inhibition. 
The reduction in HCV RNA was sustained over the course of treatment, and was gradually lost once 
the inhibitor was withdrawn. The miR-122 binding region of HCV RNA was examined by deep 
sequencing in samples taken from the high dose animals before, during and after therapy. No adaptive 
mutations were detected in this region, which is very encouraging [26]. This suggests that miR-122 
cannot be replaced by a different miRNA, which is supported by the previous observation that 
mutation of miR-122 seed match 1 to a miR-21 seed match does not allow miR-21 to regulate HCV 
[16]. It is possible that mutations might arise elsewhere in the HCV genome, or over a longer   
time-course of treatment, which would allow viremia to rebound. However, the contrast with the rapid 
evolution of mutations to most drugs that directly target HCV is striking. 
The chimpanzees showed a similar increase in levels of miR-122 target mRNAs and reduction in 
total plasma cholesterol to the other animals that have been treated. One interesting difference was that 
the cholesterol reduction in chimpanzees was predominantly in low-density lipoprotein (LDL) and 
apolipoprotein Apo-B, in contrast to African green monkeys where high-density lipoprotein (HDL) 
and its apolipoprotein Apo-A1  were mainly affected [25,26]. It is probable that the results in 
chimpanzees will be more representative of human patients, so these results are encouraging when 
considering miR-122 targeting for cholesterol reduction, as high LDL levels are strongly associated 
with cardiovascular disease [34]. Numerous indicators of liver toxicity were examined, and no 
problems were detected. The only change observed was an improvement in overall liver histology in 
the high dose animals that accompanied the reduction in viral load [26]. Viruses 2010, 2                               
 
 
1389 
The HCV-infected chimpanzee model has several significant differences to human infection. 
Chimpanzees typically experience milder symptoms than human patients, and do not progress to 
cirrhosis [35]. Chronically infected chimpanzees have a permanently induced interferon system that 
does not respond to stimuli. In this, they are similar to human interferon non-responders, who have 
elevated levels of interferon and do not respond to interferon therapy. One very interesting result of 
this study was a reduction in expression of interferon-regulated genes (IRGs) accompanying the 
reduction in viral load in the animals that received the high dose therapy, or responded to the low dose 
[26].  This is encouraging as  it  suggests that miR-122 targeting might be effective in restoring a 
functional interferon system to non-responding patients, even if the miR-122 inhibitor itself does not 
fully eliminate infection. 
6. Outlook for miRNA-based therapies against HCV 
The effects of miR-122 inhibition on HCV infection in chimpanzees suggest that this method could 
provide a very exciting novel approach to HCV therapy.  
Lanford et al’s results have greatly increased our knowledge from previous cell culture studies by 
showing that there is a correlation between miR-122 activity and HCV RNA levels in infected 
chimpanzees [26]. It is reasonable to assume that SPC3649 represses HCV infection in animals by 
directly preventing the interaction between miR-122 and HCV RNA, as all evidence from cell culture 
indicates that this is the only mechanism by which miR-122 regulates HCV. Replication of HCV is lost 
completely when the miR-122 binding sites are mutated, but can be fully restored by supplementation 
with a mutant miR-122 that binds the mutant site [15-17]. This implies that the role for miR-122 in 
HCV infection is entirely dependent on its direct interaction with its binding sites. In support of this, 
regulation of HCV by miR-122 was shown to be independent of the effects of miR-122 on isoprenoid 
biosynthesis and the requirement for products of this pathway in HCV replication [20]. The lack of 
evolution of adaptive mutations and sustained response to miR-122 sequestration in infected 
chimpanzees suggests that the miR-122-HCV interaction is essential for the virus and cannot easily be 
overcome [26]. 
The exciting results in chimpanzees provide an important starting point for taking this inhibitor into 
human trials, but it is difficult to predict how effective it may be. The chimpanzee research was on too 
small a scale to draw any statistical conclusions, and it is important to bear in mind the differences in 
infection patterns in chimpanzees and humans. Analysis of miR-122 levels in HCV-infected humans 
suggests that the relationship between the miRNA and the virus may be rather more complex than in 
cultured cells. Levels of miR-122 were quantified in liver biopsies taken from patients, and showed no 
positive correlation with viral load [36]. Moreover, patients who did not respond to pegylated 
interferon-α therapy had lower miR-122 expression at the start of treatment than patients who showed 
a sustained virological response. Interferon treatment did not affect miR-122 expression [36].  
The minor reduction in HCV RNA in chimpanzees receiving a low dose of miR-122 inhibitor may 
have bearing on these observations, as this suggests that a very low level of miR-122 may be sufficient 
to support HCV replication in vivo [26]. miR-122 expression in the liver is four-fold higher than in 
cultured Huh-7 cells [37], which support highly efficient HCV replication, so the reduced levels of 
miR-122 in the interferon non-responders could be adequate for viral replication to occur. It is even Viruses 2010, 2                               
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possible that lower endogenous miR-122 in non-responding patients would make them more 
susceptible to miR-122 inhibitors as HCV therapy. The changes in interferon levels in chimpanzees 
subjected to SPC3649 treatment are also intriguing in this context, as this raises the possibility that 
miR-122 sequestration could restore an interferon response by reducing HCV load [26].  
One very encouraging feature of miR-122 inhibitors as anti-HCV therapeutics is the lack of liver 
toxicity. A major problem with the current pegylated interferon-α/ribavirin therapy is the associated 
side effects, which reduce adherence to the regime [12]. In contrast to this, the reduction in plasma 
cholesterol in response to miR-122 sequestration would actually benefit patients. However, miR-122 is 
a highly conserved, highly expressed miRNA that regulates numerous cellular targets. The 
consequences of interfering with its activity in the long term could easily be problematic, particularly 
considering the association between altered miRNA regulation and cancer [5]. It will be necessary to 
follow up the treated chimpanzees to detect any long term effects that do arise. It would seem wisest to 
apply the miR-122 inhibitor over fairly short time periods, in collaboration with other drugs that target 
other aspects of the viral life cycle, with the aim of rapidly clearing HCV infection. Alternatively, it is 
possible that miR-122 antagonism could be used to restore interferon non-responders to a state in 
which pegylated interferon-α/ribavirin can be used effectively [26]. 
If miR-122 inhibitors do prove effective as anti-HCV drugs in humans, it is almost certain that this 
will be as part of a combined therapy. The reduction in viremia in the treated chimpanzees was 
substantial but came some way short of clearing the virus, and the rebound that occurred when the 
inhibitor was withdrawn suggests that inhibition of miR-122 alone is never likely to be sufficient. This 
is an exciting time for HCV research, with particular progress in the use of HCV protease inhibitors. 
Two such inhibitors, telaprevir and boceprevir, are now in advanced clinical trials and have shown 
promising viral clearance rates [38]. However, resistance to the inhibitors has been detected, so there is 
still a need for new drugs for which this is less of a problem. Both trials combine the protease 
inhibitors with pegylated interferon-α/ribavirin, so toxicity remains a problem and makes the treatment 
unsuitable for many patients [38]. The development of different combination therapies based solely on 
small molecules is desirable. Anti-miR-122 will be an important contributor to these combined 
therapies because evolution to avoid its effects does not seem to occur [26]. 
The LNA and phosphorothioate-modified SPC3649 appears to possess all the necessary 
characteristics of a highly effective, non-toxic, miR-122 inhibitor in animals [26]. This inhibitor, or a 
very similar molecule, is the most likely candidate to be used in any anti-HCV therapy based on 
targeting miR-122. Santaris Pharma is intending to take this molecule, now known as miravirsen, into 
phase II clinical trials in late 2010, following completion of a phase I dose escalation trial in healthy 
adult males. A consortium between Regulus and Glaxo Smith Kline is also planning clinical trials to 
start in 2011 using an antisense oligonucleotide approach to target miR-122, but has not yet identified 
a candidate molecule for clinical development. Other methods of miRNA inhibition are also possible, 
and developments in these strategies in the future may provide useful approaches to target this 
miRNA, perhaps over different timescales or as part of different drug combinations.  
In conclusion, there are several features of miR-122 inhibition that make it highly attractive as a 
means of targeting HCV infection. The conservation of the miR-122 binding sites across all HCV 
genotypes is important; theoretically, inhibitors would be expected to be equally efficient in treatment 
of any infection, although in reality it is likely that other features of individual infections will modulate Viruses 2010, 2                               
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the response to anti-miR-122. HCV shows a strong requirement for the miR-122 interaction in cell 
culture in both infectious virus and replicon systems, based on different genotypes [15,17,18]. The 
recent research in chimpanzees demonstrates that miR-122 is also important in HCV infection in 
animals [26]. Targeting a conserved host factor avoids many of the problems of viral evasion of drug 
therapy. miR-122 can be effectively inhibited by small molecules that are administered intravenously, 
and inhibition appears to be non-toxic. The most closely examined inhibitor, SPC3649, shows good 
pharmacokinetics with sustained, reversible inhibition of the miRNA [26]. The results of human trials 
of miR-122 inhibitors will be very interesting. 
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